NeuroDerm Ltd.

84 articles about NeuroDerm Ltd.

• NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

  1/9/2023

  NeuroDerm Ltd. today announced highly positive results from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
• 

  Global Roundup: Ginkgo/Microba Autoimmune Pact and New Parkinson's Data

  4/7/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
• 

  AAN Spotlight: Multiple System Atrophy, Migraine, ALS and Parkinson’s

  4/7/2022

  The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.

• BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease

  4/4/2022

  NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data for ND0612 at the American Academy of Neurology Annual Meeting (in Seattle, April 2-7, and virtually, April 24-27).

• Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson's Disease Presentations at American Academy of Neurology Annual Meeting

  4/18/2018

  Mitsubishi Tanabe Pharma America, Inc. and NeuroDerm Ltd. announced presentations on Parkinson's disease (PD) at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.

• Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm

  10/18/2017

  The acquisition was approved by NeuroDerm's shareholders on September 12, 2017

• NeuroDerm Shareholders Approve Proposed Acquisition By Mitsubishi Tanabe

  9/12/2017

• NeuroDerm Announces Second Quarter 2017 Financial Results

  8/4/2017

• NeuroDerm Announces Extraordinary General Meeting Of Shareholders To Approve Acquisition By Mitsubishi Tanabe

  8/2/2017

• Results Of NeuroDerm’s ND0612H Phase II Trial Presented In Oral Session At The 3rd Congress Of The European Academy Of Neurology

  6/27/2017

• NeuroDerm Presents Six Posters At The 21st International Congress Of Parkinson’s Disease And Movement Disorders

  6/8/2017

• EMA Accepts Design Of NeuroDerm's ND0612 Phase III Indigo Efficacy Trial

  6/6/2017

• NeuroDerm Presents ND0612H Phase II Trial Results In Late-Breaking Poster Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders

  6/5/2017

• NeuroDerm ND0612H Phase II Trial Results To Be Presented In Late-Breaking Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders

  5/23/2017

• NeuroDerm Announces First Quarter 2017 Financial Results

  5/11/2017

• NeuroDerm To Host Investor Day On April 21, 2017

  4/10/2017

• NeuroDerm Announces Fourth Quarter And Full Year 2016 Financial Results

  3/30/2017

• NeuroDerm To Host Fourth Quarter And 2016 Fiscal Year Financial Results Conference Call On March 30, 2017

  3/21/2017

• NeuroDerm Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting

  3/1/2017